These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11020130)

  • 21. An open-label study of botulinum toxin A for treatment of tardive dystonia.
    Tarsy D; Kaufman D; Sethi KD; Rivner MH; Molho E; Factor S
    Clin Neuropharmacol; 1997 Feb; 20(1):90-3. PubMed ID: 9037579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Jaw-opening oromandibular dystonia secondary to Wilson's disease treated with botulinum toxin type A.
    Teive HA; Klüppel LE; Munhoz RP; Becker N; Müller PR; Werneck LC
    Arq Neuropsiquiatr; 2012 Jun; 70(6):407-9. PubMed ID: 22699536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with botulinum toxin injections does not change brainstem interneuronal excitability in patients with cervical dystonia.
    Valls-Sole J; Tolosa ES; Marti MJ; Allam N
    Clin Neuropharmacol; 1994 Jun; 17(3):229-35. PubMed ID: 9316668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
    Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J
    Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cervical dystonia: clinical and therapeutic features in 85 patients.
    Camargo CH; Teive HA; Becker N; Baran MH; Scola RH; Werneck LC
    Arq Neuropsiquiatr; 2008 Mar; 66(1):15-21. PubMed ID: 18392407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia.
    Dressler D; Adib Saberi F
    J Neurol Neurosurg Psychiatry; 2007 Jan; 78(1):108-9. PubMed ID: 17172580
    [No Abstract]   [Full Text] [Related]  

  • 28. Quantitative electromyography-guided botulinum toxin treatment of cervical dystonia.
    Finsterer J; Fuchs I; Mamoli B
    Clin Neuropharmacol; 1997 Feb; 20(1):42-8. PubMed ID: 9037572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis.
    Posada IJ; Ramos A
    Parkinsonism Relat Disord; 2011 Aug; 17(7):570-2. PubMed ID: 21531161
    [No Abstract]   [Full Text] [Related]  

  • 30. Atypical posttraumatic dystonia treated successfully by botulinum toxin injection.
    Lee SY; Lim JY
    Am J Phys Med Rehabil; 2015 Mar; 94(3):246-9. PubMed ID: 25415396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of focal dystonia of the extensor hallucis longus muscle with botulinum toxin injection: a case report.
    Sherman AL; Willick SP; Cardenas DD
    Arch Phys Med Rehabil; 1998 Oct; 79(10):1303-5. PubMed ID: 9779689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of mirror dystonia as guidance for injection of botulinum toxin in writing dysfunction.
    Singer C; Papapetropoulos S; Vela L
    J Neurol Neurosurg Psychiatry; 2005 Nov; 76(11):1608-9. PubMed ID: 16227568
    [No Abstract]   [Full Text] [Related]  

  • 33. Botulinum toxin (Botox, Dysport, and Myobloc): pharmacology 101.
    Wynn RL
    Gen Dent; 2011; 59(2):88-90. PubMed ID: 21903516
    [No Abstract]   [Full Text] [Related]  

  • 34. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
    Silberstein S; Mathew N; Saper J; Jenkins S
    Headache; 2000 Jun; 40(6):445-50. PubMed ID: 10849039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia.
    Dressler D
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):604; author reply 604. PubMed ID: 12397170
    [No Abstract]   [Full Text] [Related]  

  • 36. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
    Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
    Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
    Laubis-Herrmann U; Fries K; Topka H
    Eur Neurol; 2002; 47(4):214-21. PubMed ID: 12037435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of botulinum toxin therapies.
    Madalinski MH; Slawek J
    Dis Colon Rectum; 2003 Dec; 46(12):1719-20. PubMed ID: 14668605
    [No Abstract]   [Full Text] [Related]  

  • 39. Botulinum Toxin A in bruxers. One year experience.
    Redaelli A
    Saudi Med J; 2011 Feb; 32(2):156-8. PubMed ID: 21301762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cervical dystonia: from pathophysiology to pharmacotherapy.
    Patel S; Martino D
    Behav Neurol; 2013; 26(4):275-82. PubMed ID: 22713419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.